Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Monte Rosa Therapeutics (GLUE) Assets Average (2023 - 2025)

Monte Rosa Therapeutics (GLUE) has 3 years of Assets Average data on record, last reported at $409.7 million in Q3 2025.

  • For Q3 2025, Assets Average rose 24.31% year-over-year to $409.7 million; the TTM value through Sep 2025 reached $409.7 million, up 24.31%, while the annual FY2024 figure was $371.2 million, N/A changed from the prior year.
  • Assets Average reached $409.7 million in Q3 2025 per GLUE's latest filing, up from $376.4 million in the prior quarter.
  • Across five years, Assets Average topped out at $416.0 million in Q1 2025 and bottomed at $265.4 million in Q3 2023.
  • Average Assets Average over 3 years is $333.6 million, with a median of $317.5 million recorded in 2024.
  • Peak YoY movement for Assets Average: grew 3.95% in 2024, then surged 45.82% in 2025.
  • A 3-year view of Assets Average shows it stood at $277.9 million in 2023, then skyrocketed by 35.61% to $376.9 million in 2024, then increased by 8.7% to $409.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Assets Average were $409.7 million in Q3 2025, $376.4 million in Q2 2025, and $416.0 million in Q1 2025.